FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy

Y Zhang; AJ Edgley; AJ Cox; AK Powell; B Wang; AR Kompa; DI Stapleton; SC Zammit; SJ Williams; H Krum; RE Gilbert; DJ Kelly

Journal article

FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy

Y Zhang, AJ Edgley, AJ Cox, AK Powell, B Wang, AR Kompa, DI Stapleton, SC Zammit, SJ Williams, H Krum, RE Gilbert, DJ Kelly

European Journal of Heart Failure | Published : 2012

DOI: 10.1093/eurjhf/hfs011

Abstract

Aims Cardiac remodelling in diabetes includes pathological accumulation of extracellular matrix and myocyte hypertrophy that contribute to heart dysfunction. Attenuation of remodelling represents a potential therapeutic target. We tested this hypothesis using a new anti-fibrotic drug, FT011 (Fibrotech Therapeutics Pty Ltd), on diabetic Ren-2 rats, a model which replicates many of the structural and functional manifestations of diabetic cardiomyopathy in humans. Methods and results Homozygous Ren-2 rats were randomized to receive streptozotocin or vehicle then further randomized to FT011 (200 mg/kg/day) or vehicle treatment for 6 weeks. Prior to tissue collection, cardiac function was assesse..

View full abstract

University of Melbourne Researchers

Amanda Edgley Author

Andrew Kompa Author

Spencer Williams Author

Richard Gilbert Author

Related Projects (2)

NOVEL THERAPEUTIC STRATEGIES TO REDUCE THE BURDEN OF CHRONIC HEART FAILURE

The broad aims of the Program are to develop novel strategies in the prevention and treatment of chronic heart failure. This will involve in..

PREVENTION AND TREATMENT OF CHRONIC HEART AND KIDNEY DISEASE VIA EPIDEMIOLOGICAL, PHARMACOLOGICAL DEVICE AND CELL-BASED APPROACHES

Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite re..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

We thank Mariana Pacheco and Jemma Court from the University of Melbourne, Department of Medicine, St Vincent's Hospital for excellent animal care. D.J.K. is a an NHMRC Fellow. R. E. G. is a Canada Research Chair in Diabetes Complications and this work was supported thanks, in part, to the Canada Research Chair Program.National Health and Medical Research Council program grants 334008 and 546272, and NHMRC project grant 1005496. Diabetes Australia Research Trust.